[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Telomir Pharmaceuticals Inc (TELO)

Telomir Pharmaceuticals Inc (TELO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,218
  • Shares Outstanding, K 68,775
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,410 K
  • EBIT $ -9 M
  • EBITDA $ -5 M
  • 60-Month Beta -0.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +2.54%
on 05/19/26
1.3400 -9.70%
on 05/20/26
-0.0900 (-6.92%)
since 05/08/26
3-Month
1.1000 +10.00%
on 03/30/26
1.5000 -19.33%
on 04/29/26
-0.1200 (-9.02%)
since 03/09/26
52-Week
1.0500 +15.24%
on 02/12/26
3.1000 -60.97%
on 07/18/25
-0.7700 (-38.89%)
since 06/09/25

Most Recent Stories

More News
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical...

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic...

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner.

TELO : 1.2100 (-5.47%)
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.

TELO : 1.2100 (-5.47%)

Business Summary

Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE....

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.3033
1st Resistance Point 1.2567
Last Price 1.2100
1st Support Level 1.1867
2nd Support Level 1.1633
3rd Support Level 1.1167

See More

52-Week High 3.1000
Fibonacci 61.8% 2.3169
Fibonacci 50% 2.0750
Fibonacci 38.2% 1.8331
Last Price 1.2100
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.